Volition's nu.q® nets assay demonstrates promising results in covid-19 risk stratification and disease monitoring

Austin, texas, july 22, 2021 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working with researchers at two leading  nhs foundation trusts on two studies in covid-19 for which abstracts were released this week at the international society on thrombosis and haemostasis (isth) congress 2021. dr. jake micallef, chief scientific officer of volition said "we believe our nu.q® nets assay will have wide applicability for monitoring diseases with a nets component (such as covid-19, sepsis, autoimmune diseases and cancer) and potentially to risk stratify patients for treatment selection.
VNRX Ratings Summary
VNRX Quant Ranking